Raymond James Financial Services Advisors’s RVL Pharmaceuticals plc Ordinary Shares RVLP Stock Holding History

Raymond James Financial Services Advisors’s Portfolio RVLP Stock Details RVLP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	–	Sell	-103,037	Closed	-$8.92K	–	3475
2023 Q3	$8.92K	Buy	103,037 +73,518	+249%	+$21.2K	﹤0.01%	3231
2023 Q2	$16.5K	Hold	29,519	–	–	﹤0.01%	3185
2023 Q1	$33.7K	Hold	29,519	–	–	﹤0.01%	3152
2022 Q4	$33.1K	Hold	29,519	–	–	﹤0.01%	3120
2022 Q3	$62K	Buy	+29,519	New	+$57.4K	﹤0.01%	3065

Other funds holding RVLP

XTX Topco George Town, Cayman Islands $5.75B AUM 30.56% 1-Year Est. Return

RJA

Raymond James & Associates St Petersburg, Florida $164B AUM 33.91% 1-Year Est. Return

Raymond James Financial Services Advisors's RVLP Position: Q4 2023 in Review

Raymond James Financial Services Advisors sold out of RVL Pharmaceuticals plc Ordinary Shares (RVLP) in Q4 2023, closing a stake of 103,037 shares — an estimated $8.92K sold.

Raymond James Financial Services Advisors first reported a position in RVLP in Q3 2022 and held it in 5 quarters. The position peaked at $62K in Q3 2022. 3 funds tracked by Wall St. Rank hold RVLP as of Q4 2023.

Raymond James Financial Services Advisors reported no remaining RVL Pharmaceuticals plc Ordinary Shares position as of Q4 2023 after selling out during the quarter.
Raymond James Financial Services Advisors sold 103,037 RVL Pharmaceuticals plc Ordinary Shares shares in Q4 2023, an estimated $8.92K.
Raymond James Financial Services Advisors first reported a position in RVL Pharmaceuticals plc Ordinary Shares in Q3 2022 and held it in 5 quarters.
Raymond James Financial Services Advisors's RVL Pharmaceuticals plc Ordinary Shares position peaked at $62K in Q3 2022.
3 funds tracked by Wall St. Rank held RVL Pharmaceuticals plc Ordinary Shares as of Q4 2023.

Based on Raymond James Financial Services Advisors's 13F filing for Q4 2023, filed 16 Jan 2024.